Allied Corp. announced that following an extensive regulatory review, it has received ANVISA approval for Brazilian importation.
On April 27th, 2022, Allied announced the signing of a forward purchase agreement for the manufacturing and sell-through of medical products destined for Brazil. On June 9th, 2022, Allied further announced the successful initial shipment for this forward purchase agreement. By way of this announcement, Allied has now obtained ANVISA approval for these transactions.
The Brazilian Health Regulatory Agency (ANVISA) controls the importation of medical products to the Brazilian market. ANVISA’s role is to promote the protection of the population’s health by executing sanitary control of the production, marketing, and use of products and services subject to health regulation, including related environments, processes, ingredients, and technologies, as well as the control of ports, airports, and borders.
Allied has now met the required regulatory requirements for Brazilian ANVISA and is now importing into the Brazilian medical market.
“This is an exciting day for Allied. With ANVISA’s recent approval of our products, it opens the Brazilian market for Allied. Through partnering with large medical groups in Brazil, we will now be able to bring the Allied products to the patients that need the medicine. The area of Sao Paulo serves over 22 million people. Given this size, we will be focusing on developing recurring sales into this area and also expanding across the Brazilian national market,” said James McMillan, Chief Commercial Officer for Allied Corp.
For more information: